Figure 3
From: Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer
UM-UC-3, UM-UC-6, and UM-UC-9 cells were treated once with increasing concentrations of dacomitinib (0.02 to 2 µmol/L for 5 h) or DMSO [untreated control (U)] (2% FBS-culture media). The effects on unphosphorylated and phosphorylated protein expression were measured by Western blot. In all three cell lines, dacomitinib inhibited baseline EGFR (Y1068) phosphorylation. In UM-UC-6 cells, dacomitinib also inhibited baseline ERK (T202/Y204), Akt (S473) phosphorylation. The expression of p-HER2, and unphosphorylated proteins appeared unaffected.